Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Sopharma AD-Sofia's Beta is -0.1138.
Sopharma AD-Sofia (WAR:SPH) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Sopharma AD-Sofia Beta Related Terms
Sopharma AD-Sofia Beta Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Beta can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma AD-Sofia's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Beta vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Beta distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Sopharma AD-Sofia (WAR:SPH) has a Beta of -0.1138 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Beta too high?
Sopharma AD-Sofia's current Beta is -0.1138. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Beta compare to MCK and COR?
Sopharma AD-Sofia's Beta of -0.1138 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Distribution company?
A good Beta depends on the Medical Distribution industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Beta is -0.1138. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.56, compared to a current price of zł7.92 — trading 41.6% below its estimated fair value. The current Beta is -0.1138. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Beta is -0.1138 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.92 is trading 41.6% below its estimated GF Value™ of zł13.56.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Beta: -0.1138
GF Value™: zł13.56 vs. price of zł7.92 (41.6% below fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
